CN100345548C - 用于治疗骨折的药物 - Google Patents

用于治疗骨折的药物 Download PDF

Info

Publication number
CN100345548C
CN100345548C CNB008117659A CN00811765A CN100345548C CN 100345548 C CN100345548 C CN 100345548C CN B008117659 A CNB008117659 A CN B008117659A CN 00811765 A CN00811765 A CN 00811765A CN 100345548 C CN100345548 C CN 100345548C
Authority
CN
China
Prior art keywords
bone
use according
pamidronate
stimulation
fracture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008117659A
Other languages
English (en)
Chinese (zh)
Other versions
CN1370071A (zh
Inventor
戴维·G·利特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Alexandra Hospital for Children
Original Assignee
Royal Alexandra Hospital for Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hospital for Children filed Critical Royal Alexandra Hospital for Children
Publication of CN1370071A publication Critical patent/CN1370071A/zh
Application granted granted Critical
Publication of CN100345548C publication Critical patent/CN100345548C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB008117659A 1999-08-19 2000-08-17 用于治疗骨折的药物 Expired - Fee Related CN100345548C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
AUPQ2325 1999-08-19

Publications (2)

Publication Number Publication Date
CN1370071A CN1370071A (zh) 2002-09-18
CN100345548C true CN100345548C (zh) 2007-10-31

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008117659A Expired - Fee Related CN100345548C (zh) 1999-08-19 2000-08-17 用于治疗骨折的药物

Country Status (16)

Country Link
EP (1) EP1214079A4 (pt)
JP (1) JP2003507426A (pt)
KR (1) KR20020027562A (pt)
CN (1) CN100345548C (pt)
AU (1) AUPQ232599A0 (pt)
BR (1) BR0013416A (pt)
CA (1) CA2381302A1 (pt)
HK (1) HK1048441B (pt)
HU (1) HUP0202396A3 (pt)
IL (1) IL148166A0 (pt)
NO (1) NO20020784L (pt)
NZ (1) NZ517538A (pt)
PL (1) PL353485A1 (pt)
SK (1) SK2382002A3 (pt)
WO (1) WO2001013922A1 (pt)
ZA (1) ZA200202160B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496624T1 (de) 2001-02-06 2011-02-15 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
EP1383509A4 (en) * 2001-04-03 2005-10-26 Royal Alexandra Hosp Children MEDICAMENT FOR USE IN BONE TRAINING
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
KR101315925B1 (ko) 2005-10-27 2013-10-08 토멘 메디칼 아게 치과용 임플란트 및 그의 제조 방법
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN114532937B (zh) * 2020-11-18 2024-11-01 中国人民解放军海军军医大学第一附属医院 一种小肠镜辅助装置

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021266A1 (en) * 1993-03-24 1994-09-29 Leiras Oy The use of bisphosphonates in bone surgery
CN1146152A (zh) * 1994-04-21 1997-03-26 麦克公司 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用
US5616560A (en) * 1991-12-17 1997-04-01 The Procter & Gamble Company Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
CN1226253A (zh) * 1996-06-28 1999-08-18 利物浦大学 甾体二膦酸酯

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616560A (en) * 1991-12-17 1997-04-01 The Procter & Gamble Company Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
WO1994021266A1 (en) * 1993-03-24 1994-09-29 Leiras Oy The use of bisphosphonates in bone surgery
CN1146152A (zh) * 1994-04-21 1997-03-26 麦克公司 二膦酸盐在矫形假体移植后在抑制骨再吸收中的应用
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
CN1226253A (zh) * 1996-06-28 1999-08-18 利物浦大学 甾体二膦酸酯

Also Published As

Publication number Publication date
NZ517538A (en) 2003-07-25
WO2001013922A1 (en) 2001-03-01
PL353485A1 (en) 2003-11-17
CN1370071A (zh) 2002-09-18
HUP0202396A3 (en) 2005-02-28
KR20020027562A (ko) 2002-04-13
ZA200202160B (en) 2003-08-27
AUPQ232599A0 (en) 1999-09-09
EP1214079A4 (en) 2004-03-24
BR0013416A (pt) 2002-04-30
HUP0202396A2 (hu) 2002-11-28
HK1048441A1 (en) 2003-04-04
JP2003507426A (ja) 2003-02-25
NO20020784D0 (no) 2002-02-18
SK2382002A3 (en) 2002-09-10
EP1214079A1 (en) 2002-06-19
IL148166A0 (en) 2002-09-12
HK1048441B (zh) 2008-02-22
NO20020784L (no) 2002-02-18
CA2381302A1 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
Yıldız et al. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model
CN1233325C (zh) 治疗骨坏死和处理有发展为骨坏死危险的患者用的药物
CN100345548C (zh) 用于治疗骨折的药物
Al-Mahalawy et al. Effects of cisplatin chemotherapy on the osseointegration of titanium implants
Abtahi et al. Bisphosphonate coating might improve fixation of dental implants in the maxilla: a pilot study
Cuairán et al. Local application of zoledronate enhances miniscrew implant stability in dogs
Nakagawa et al. Effects of metformin on the prevention of bisphosphonate-related osteonecrosis of the jaw-like lesions in rats
Masuda et al. Antrostomy preparation for maxillary sinus floor augmentation using drills or a sonic instrument: A microcomputed tomography and histomorphometric study in rabbits
Lotz et al. Ibandronate treatment before and after implant insertion impairs osseointegration in aged rats with ovariectomy induced osteoporosis
Apostu et al. Tibolone, alendronate, and simvastatin enhance implant osseointegration in a preclinical in vivo model
Altay et al. Effect of systemic oxytocin administration on new bone formation and distraction rate in rabbit mandible
Matsuzaki et al. Effect of post-osseointegration loading magnitude on the dynamics of peri-implant bone: a finite element analysis and in vivo study
Yu et al. Effects of bisphosphonates on osseointegration of dental implants in rabbit model
CN1173704C (zh) 伊班卓酸盐在促进内假体骨整合中的应用
Song et al. Semaphorin3A promotes osseointegration of titanium implants in osteoporotic rabbits
Küçük et al. Comparison of local and systemic alendronate on distraction osteogenesis
Alshahrani et al. Ranitidine impairs bone healing and implant osseointegration in Rats' tibiae
Lee et al. Mechanical Loading Alleviates BRONJ‐Like Lesions Around Implants Under Osteoporotic Conditions: An In Vivo Experimental Model
Siqueira et al. Resonance frequency analysis of dental implants with 2 types of surface treatment submitted to immediate loading: a prospective clinical study
RU2651363C1 (ru) Способ остеосинтеза перелома нижней челюсти с одновременным устранением адентии
Zayed et al. Outcomes of Mandibular Overdentures Supported by Four Short Implants Combined with Photobiomodulation Therapy.
AU781068B2 (en) Drug for treating fractures
Remizova et al. Personalized approach to the choice of orthopedic design depending on the predicted stability of implants
Agrawal et al. Is bone density a success criteria in dental implants
Rodriguez et al. Maxillary Sinus Lift with Summer Technique and Short Implants: A Case Study

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1048441

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071031

Termination date: 20090817